---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-004116"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2026-05-19T20:05:46+00:00"
generated_at: "2026-05-19T21:32:21.274943+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma closes $6.0M public offering with up to $12M additional warrant proceeds

## Summary
- Gross proceeds $6.0M from 12,000,000 units at $0.50/unit; closed May 19, 2026.
- Each unit includes one share (or pre-funded warrant) plus two Series C warrants exercisable at $0.50 for five years.
- Potential additional $12.0M if Series C warrants fully exercised; no assurance given.
- Net proceeds for general corporate purposes and working capital.
- Aegis Capital Corp acted as placement agent with 7% fee plus 2% expense allowance.

## SEC filing metadata
- accession: 0001683168-26-004116
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2026-05-19T20:05:46+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316826004116/0001683168-26-004116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316826004116/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-004116
- JSON: https://secwatch.observer/filing/0001683168-26-004116.json
- Plain text: https://secwatch.observer/filing/0001683168-26-004116.txt

## Key facts
- Material Agreements
  Sunshine Biopharma Inc. entered into Placement Agent Agreement with Aegis Capital Corp. valued at approximately $6 million (effective 2026-05-18).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Aegis Capital Corp.
  - Value: approximately $6 million
  - Effective: 2026-05-18
  source text: On May 18, 2026, Sunshine Biopharma Inc. (the “Company”) entered into a placement agent agreement (the “Placement Agent Agreement”) with Aegis Capital Corp. (the “Placement Agent”), in connection with a best efforts public offering
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316826004116/0001683168-26-004116-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.